G ait speed is a simple but important indicator of functional status in older adults and a strong predictor of mortality and other health-related outcomes.
1,2 A growing body of evidence has identified a relationship between chronic inflammation, age-related functional decline, and risk of disability. 3 Several studies indicate that statins have anti-inflammatory effects beyond their cholesterol-lowering and antiatherosclerosis properties. 4 For these reasons, statins could have a protective effect on age-related functional decline.
Current evidence on the association between statin use and physical function decline in older adults is mixed. [5] [6] [7] [8] [9] [10] [11] [12] [13] Studies whose sample consisted primarily of individuals with peripheral arterial disease (PAD) have reported that statin users had less annual decline in walking speed or distance than nonusers, [5] [6] [7] [8] although these effects were modest, and their clinical relevance is unclear. In addition, four of the studies that were not restricted to individuals with PAD did not find associations between statin use and self-reported or other physical function measures, [9] [10] [11] [12] whereas one study found that fast walking speed of users of lipid-lowering medication declined 25% slower than that of nonusers. 13 Previous studies show that the criterion for substantial change in decline in gait speed for clinical and research use is approximately 0.10 m/s, which was strongly associated with morbidity and mortality in older adults. 2, 14 Given these conflicting findings and the importance of maintaining adequate physical function, the objective of the current study was to examine the association between statin use and risk of decline in gait speed of 0.1 m/s or more in community-dwelling older adults. The hypothesis was that statin use would be protective for the development of decline in gait speed of 0.1 m/s or more.
METHODS

Study Design, Sample, and Data Source
This longitudinal study used data from the Health, Aging and Body Composition (Health ABC) Study, which enrolled 3,075 white and black adults aged 70-79 without mobility problems. 15 Participants were recruited in 1997-98 from a random sample of Medicare beneficiaries residing in Pittsburgh, Pennsylvania, and Memphis, Tennessee. The sample for the current study included 2,405 participants from 1998-99 who had medication and 20-m gait speed data (obtained for the first time). The institutional review boards of the Universities of Pittsburgh, Tennessee, and California at San Francisco approved the study, and written informed consent was obtained from each participant.
Data Collection and Management
Data were collected during annual in-person visits from 1998 to 2003 from blood tests; physiological measurements using standardized methods; and responses to structured questionnaires regarding demographic characteristics, multiple aspects of health behavior, and health status. 15 The Health ABC morbidity and mortality committee centrally adjudicated incident comorbidities examined in the current study (coronary heart disease (CHD), congestive heart failure (CHF), stroke, PAD) based on conclusive evidence from hospitalization or death records. 15 Prevalent disease is based on self-report of or medication use for a certain disease.
Prescription medication information was collected annually from 1998 to 2003, except in 2000-01. Participants were asked to bring all prescription medications taken in the previous month, and trained research assistants transcribed the drug name, strength, and dosage from the medication bottle, and participants reported number of units taken in the previous day, week, or month and whether the medication was taken regularly or as needed. This medication information was coded using the Iowa Drug Information Service and entered into a computerized database. 16 
Primary Outcome Measures
Usual gait speed was measured over a 20-m course in an unobstructed corridor annually from 1998 to 2003. Timing started with the first step over the starting line and ended at the first footfall over the finishing line. The primary outcome variable was decline in gait speed of 0.1 m/ s or more in the following year of statin use, based on previous studies.
2,14
Primary and Secondary Independent Variables
Statin use was identified according to Iowa Drug Information Service codes 24060202 to 24060208. The primary independent variable was use versus no use of statins at baseline (1998-99) and annually (as a time-varying variable). Several secondary independent variables were created for lipophilicity and standardized daily dose (SDD). To create the SDD measure, the daily dose was first calculated by multiplying the number of dosage forms taken the previous day according to medication strength. Then the daily dose was divided by the equivalent dose of that statin that has been reported to decrease low-density lipoprotein cholesterol by 37%. 17 The following daily doses were considered to equal 1 U of equivalent dose: atorvastatin 10 mg, fluvastatin 80 mg, lovastatin 40 mg, pravastatin 40 mg, simvastatin 20 mg, rosuvastatin 5 mg. 17 SDD was categorized as low dose (<1 SDD), moderate dose (1 SDD), and high dose (>1 SDD), based on the distribution of the data and clinical relevance. Finally, a dichotomous measure was created in which statins were categorized as being lipophilic (lovastatin, simvastatin, atorvastatin, fluvastatin) or hydrophilic (pravastatin, rosuvastatin). 18 
Covariates
Several characteristics that could confound or modify the association between statin use and gait speed were adjusted for in the analyses and grouped into four domains: demographic characteristics, health-related behaviors, health status, and access to health care. Demographic variables included baseline age, sex, race (black or white), study site, education (postsecondary education, high school graduate, or <high school graduate), and living status (alone or not alone) as a time-varying variable.
Health-related behaviors included smoking status, alcohol use (current, past, never), and self-report of doing moderate-to high-intensity exercise in the previous week (yes vs no) as time-varying variables. Health status factors for which statins may be indicated were characterized as time-varying dichotomous measures (present vs absent) for adjudicated comorbidities including CHD, stroke, and PAD. 19 Time-varying dichotomous measures (present vs absent) were used for self-reported hypertension, diabetes mellitus, CHF, pulmonary disease (baseline), osteoarthritis, and Parkinson's disease (baseline). Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate of less than 60 mL/min. 20 A time-varying dichotomous variable was created for self-rated health (good to excellent vs fair to poor). ) and a continuous variable for average total body mass (kg) were created. In addition, voluntary isokinetic knee extensor strength (average maximum torque (Nm)) was considered as a time-varying continuous variable. 21 Time-varying dichotomous variables were created for cognitive impairment (Modified Mini-Mental State Examination score <80) 22 and high depressive symptoms (Center for Epidemiologic Studies Depression Scale score >15).
23 Several time-varying dichotomous covariates (yes vs no) of the use of medications related to falls and mobility problems (benzodiazepines, angiotensin-converting enzyme inhibitors (ACEIs), anticholinergic medications, nonsteroidal anti-inflammatory drugs (NSAIDs), and other medications with anti-inflammatory effects (systematic glucocorticoids; immunosuppressive medications; some medications for rheumatoid arthritis, asthma, inflammatory bowel disease, systemic lupus erythematous, other systemic inflammatory diseases)) were controlled for in the analyses. 24 A time-varying continuous variable of the number of overall prescription medications (excluding statins, benzodiazepine, ACEIs, and other medications with antiinflammatory effects) was included. 25 Two time-varying dichotomous access to healthcare factors (yes vs no) were created (having an influenza vaccination in the past year (as a proxy related to an individual's care-seeking behavior and access to health care to adjust for healthy user effect and a provider's availability) 26 and having prescription drug coverage), to account for individuals who had and did not have insurance coverage over time.
Primary and Secondary Statistical Analyses
Appropriate descriptive statistics were used to summarize participant characteristics and main analytical variables. Statin exposure was defined as use in the year preceding ascertainment of gait speed measures. Multivariable generalized estimating equation models were used to examine the association between statin use and decline in gait speed of 0.1 m/s or more. 27 An autoregressive working correlation structure was used to account for potential multiple years of data from the same participants and the resulting stochastic nonindependence of observations. 27 In the final multivariable models, adjusted odds ratios (AORs) and 95% confidence intervals (CIs) for statin use were computed, adjusting for demographic characteristics, potential confounders by indication, gait speed measures in previous years, a factor related to access to health care, and covariates with a P < .15 from a forward selection procedure. Secondary analyses used a similar approach that adjusted for the same covariates but included other operational definitions of statin use as main predictors to test doseresponse and lipophilicity relationships. All analyses were performed using SAS version 9.3 (SAS Institute, Inc., Cary, NC).
RESULTS
The mean age of the 2,405 sample participants was 74.6, 51% were female, 37% were black, 63% had prescription medication coverage, and 16.2% used statins (Table 1) . Statin users were younger on average and more likely to be white, to be from the Pittsburgh site, to have prescription drug coverage, to have smoked previously, to drink alcohol currently, to perform high-or moderate-intensity exercise, and to have more chronic comorbidities (hypertension, diabetes mellitus, CHD, CHF, stroke, PAD, CKD) than nonusers. Statin users were also more likely to take benzodiazepines, ACEIs, and multiple prescription drugs.
At baseline, 48% of statin users used low doses, and 86% took lipophilic statins (Table 2) Statin use was not associated with decline in gait speed of 0.1 m/s or more (AOR = 0.90, 95% CI = 0.77-1.06) ( Table 3 ). Statistically nonsignificant differences were also seen in high-and moderate-dose and lipophilic and hydrophilic statin use, although only a 22% lower risk of decline in gait speed in low-dose users than in statin nonusers was found to be statistically significant (AOR = 0.78, 95% CI = 0.61-0.99), which was mainly determined by the results of the 1999-2000 follow-up.
DISCUSSION
The overall results of this study demonstrated no substantial associations between statin use and decline in gait speed of 0.1 m/s or more, which has been found to be related to self-reported morbidity and mortality, in a large elderly community dwelling sample. These overall results are consistent with studies conducted in individuals without PAD. [9] [10] [11] [12] Large cohort studies have found that statin use is not associated with self-reported mobility limitations; 9 objective physical performance measures 10 and incidence of frailty in postmenopausal women; 11 and muscle strength, balance, mobility, and falls, 12 although two randomized trials 7, 8 and three longitudinal studies 5, 6, 13 in individuals with PAD have reported that statin use is associated with lower risk of decline in gait speed than in nonusers. Possible explanations of these differences include use of different populations (e.g., women only, younger baseline age), less-precise self-reported outcomes, modest improvement in using continuous outcomes but possible lack of clinical relevance, and lack of attention to dose response.
What are the clinical implications of these study findings for older adults? Given that statin use may continue to increase because of the new 2013 American College of Cardiology/American Heart Association guideline on the Treatment of Blood Cholesterol, 28 the overall nonsignificant association between statin use and decline in gait speed is reassuring because it was possible that adverse statin-related muscular events in older adults could have resulted in slower gait speed. Generally, the muscle-related adverse effects of statin use are associated with higher doses and blood levels. 29 These adverse events may occur in up to 10% of adults receiving high-dose statins, 30 although the precise estimate is unknown for older frail adults. Low-dose statin use, as shown in the results of the current study, may minimize muscle-related adverse effects in older adults and therefore may be less likely to counteract beneficial effects of statins.
Strengths of this study include the prospective design in a large community-dwelling older-adult sample; medication information collected using a state-of-the-art approach; availability of serially obtained, standardized gait speed measures; and adjustment for numerous potential confounders, although inherent to longitudinal studies examining older adults, potential survivor bias should be considered. The results from a sensitivity analysis, restricted to participants alive during all study years .001 from chi-square or t-test between statin users and nonusers. (1998) (1999) (2000) (2001) (2002) (2003) , yielded similar results (data not shown). Second, medication data were collected at fixed nearly yearly points in time, preventing documentation of the exact date on which statins were initiated, dosage was changed or discontinued, or adverse events that could affect gait speed occurred. Moreover, unmeasured confounders such as adherence to medications cannot be excluded. Last, this sample was drawn from two U.S. cities and may not be generalizable to other populations.
CONCLUSION
These results suggest no greater decline in gait speed with statin use than with nonuse in community-dwelling older adults. Future studies are needed to confirm the inconclusive, observed lower risk of decline in gait speed with low-dose statin use than with nonuse in varied older adult populations.
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